When Liana Woskie reviewed the 642,700 medication abortions reported in the U.S. in 2023, she saw more than numbers—she saw a healthcare system adapting under pressure. Mifepristone, the medication at the heart of that care, remains accessible for now, thanks to a recent U.S. Supreme Court decision that preserves telehealth prescriptions and mail delivery while legal challenges continue. This ruling keeps open a critical pathway for patients, especially those in rural areas or states with strict abortion bans, where virtual care may be the only option for safe, clinician-supported treatment. The drug, used in 63% of all abortions in the country, is not just vital for abortion care—it also helps manage early miscarriages and treats Cushing syndrome, a rare hormonal disorder. Its role in reproductive health is both broad and deeply personal.
The science behind mifepristone is clear: paired with misoprostol, it is over 95% effective in ending early pregnancies, with serious complications occurring in less than 0.4% of cases. For decades, data from clinical trials, FDA monitoring, and real-world use have consistently affirmed its safety. Yet confusion persists. Some emergency visits after medication abortion are due to expected symptoms or follow-up needs—not drug-related harm—but these are often misrepresented as safety risks. Woskie, an assistant professor of community health, emphasizes that “the steady increase in medication abortions reflects patient preference for a private, affordable, and noninvasive option,” especially as in-person clinics close and access to procedural care shrinks.
Telehealth has become a lifeline. In a standard virtual visit, a certified clinician assesses a patient’s medical history and pregnancy timeline, then mails the medication with detailed instructions. Certified pharmacies handle delivery, ensuring patients receive care without travel or exposure. But this system hangs in legal limbo. While the Supreme Court’s action maintains the status quo, ongoing litigation could still restrict how and where mifepristone is prescribed. If telehealth access is curtailed, the burden will fall hardest on those already marginalized—low-income individuals, people in remote areas, and those in states where abortion is heavily restricted.
Even if mifepristone access narrows, medication abortion won’t vanish. Misoprostol alone can be used, though it’s slightly less effective. But losing telehealth would mean longer delays, greater costs, and more barriers. For now, the door remains open. The path forward will depend not just on science, but on whether policy can keep pace with patient need.